Home » Newsletters » BioWorld Science

BioWorld Science

May 25, 2015

View Archived Issues

ASP-7147 shows promise in clinic for IBS-D

VPR-7 effective in murine IBD models

VBL Therapeutics discloses new drug candidate for liver fibrosis in NASH

U.S. scientists report anti-EFNA4 antibody-drug conjugates

Cypher Genomics and Celgene collaborate to discover novel genomic biomarkers

NIH extends grant to Viamet for antifungal agents for Valley fever

Baxter seeks European approval for IGSC 20% for primary immunodeficiencies

Sustained effects seen with ENV-905 Ophthalmic Implant in vivo

EMA committee recommends approval of Omidria

EMA committee hands down positive opinion for Keytruda in advanced melanoma

Merus and Selexis awarded grant to develop bispecific antibody combination products

EMA's CHMP supports approval of Repatha for high cholesterol

Stelara recommended for European approval for plaque psoriasis in adolescents

MSI-1 inhibitors block RNA binding as a new strategy for cancer treatment

Janssen to acquire license to Novo Nordisk autoimmune disease development program

Kuvan gets positive opinion from CHMP for expanded indication

Novel small-molecule disruptors of HuR-mRNA interaction show promise for cancer therapy

R-Tech Ueno completes single-dose phase I trial of RTU-1096

Bayer patents chymase inhibitors

Boehringer Ingelheim presents Brd4 inhibitors

iTeos Therapeutics discloses TDO2 inhibitors

Bristol-Myers Squibb prepares and tests GSK-3 inhibitors for Alzheimer's

Gilead Sciences patent describes development of antiviral compounds

Imbruvica recommended for European approval in Waldenstrom's macroglobulinemia

Amgen ends participation in collaboration on brodalumab development

Nivolumab receives EMA recommendation for squamous NSCLC

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...